China Approval Status of Tirzepatide
Based on the available evidence, tirzepatide has NOT been approved by Chinese regulatory authorities as of the most recent guideline data (2019). The 2019 Standards of Medical Care for Type 2 Diabetes in China explicitly lists commercially available medications in each drug class, and tirzepatide is conspicuously absent from all categories 1.
Evidence from Chinese Guidelines
The 2019 Chinese diabetes guidelines provide comprehensive lists of approved medications:
- GLP-1 receptor agonists available in China: exenatide, liraglutide, lixisenatide, and beinaglutide 1
- DPP-4 inhibitors available in China: sitagliptin, saxagliptin, vildagliptin, linagliptin, and alogliptin 1
- SGLT2 inhibitors available in China: dapagliflozin, empagliflozin, and canagliflozin 1
Tirzepatide is not mentioned in any of these lists, indicating it was not approved for use in China at the time these guidelines were published.
Clinical Trial Activity in China
However, tirzepatide has been extensively studied in Chinese populations:
- A Phase 1 study (NCT04235959) demonstrated safety, tolerability, and efficacy in Chinese patients with type 2 diabetes, with doses escalating from 2.5 mg to 15 mg weekly 2
- The SURMOUNT-CN trial (NCT05024032), conducted at 29 centers across China from September 2021 to December 2022, showed significant weight reduction (13.6% with 10 mg, 17.5% with 15 mg vs 2.3% placebo) in Chinese adults with obesity 3
- Post-hoc analyses of SURMOUNT-CN demonstrated cardiometabolic benefits and reduced 10-year diabetes risk in Chinese participants 4, 5
Global Approval Context
For reference, tirzepatide received FDA approval in the United States for:
- Type 2 diabetes in 2022 6
- Obesity in November 2023 7
- Moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024 6
Clinical Implications
If you are practicing in China and considering tirzepatide for your patients, you should verify current regulatory status with the National Medical Products Administration (NMPA), as approval status may have changed since the 2019 guideline publication. The robust clinical trial data in Chinese populations 2, 3, 4, 5 suggests regulatory submission may be underway or completed, but this cannot be confirmed from the provided evidence.
For Chinese patients with type 2 diabetes and obesity who cannot access tirzepatide, the 2019 guidelines support using approved GLP-1 receptor agonists (liraglutide, exenatide, lixisenatide, or beinaglutide) combined with SGLT2 inhibitors for similar cardiometabolic benefits 1.